SCAI consensus guidelines for device selection in femoral-popliteal arterial interventions

DN Feldman, EJ Armstrong… - … : official journal of …, 2018 - pubmed.ncbi.nlm.nih.gov
SCAI consensus guidelines for device selection in femoral-popliteal arterial interventions SCAI
consensus guidelines for device selection in femoral-popliteal arterial interventions Catheter …

Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease

C Caradu, E Lakhlifi, EC Colacchio, D Midy… - Journal of vascular …, 2019 - Elsevier
Objective An endovascular-first approach is usually recommended in femoropopliteal
occlusive disease. However, despite high technical success, plain old balloon angioplasty …

Long-term clinical effectiveness of a drug-coated balloon for the treatment of femoropopliteal lesions: five-year outcomes from the IN. PACT SFA randomized trial

JA Laird, PA Schneider, MR Jaff… - Circulation …, 2019 - Am Heart Assoc
Background: While randomized trials have demonstrated the superiority of drug-coated
balloon (DCB) angioplasty versus standard percutaneous transluminal angioplasty (PTA) in …

Drug-eluting stent versus drug-coated balloon revascularization in patients with femoropopliteal arterial disease

Y Bausback, T Wittig, A Schmidt, T Zeller… - Journal of the American …, 2019 - jacc.org
Background: Randomized trials of drug-eluting stents (DES) and drug-coated balloons
(DCB) for femoropopliteal interventions reported superior patency rates for both strategies …

The 24-month results of the Lutonix Global SFA Registry: worldwide experience with Lutonix drug-coated balloon

M Thieme, P Von Bilderling, C Paetzel… - JACC: Cardiovascular …, 2017 - jacc.org
Abstract Objectives: The Global SFA Registry sought to assess safety, clinical benefit, and
outcomes of the Lutonix 035 drug-coated balloon (DCB) in a heterogeneous, real-world …

COMPARE: prospective, randomized, non-inferiority trial of high-vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions

S Steiner, A Schmidt, T Zeller, G Tepe… - European Heart …, 2020 - academic.oup.com
Abstract Aims Drug-coated balloons (DCBs) for femoropopliteal interventions have not been
tested against each other. We aimed to directly compare efficacy and safety of a high-dose …

Impact of baseline and postprocedural intravascular ultrasound findings on 1-year primary patency after drug-coated balloon treatment of femoropopliteal lesions

K Horie, A Tanaka, M Taguri… - Journal of Endovascular …, 2022 - journals.sagepub.com
Purpose: Drug-coated balloons (DCBs) are commonly used for endovascular treatment of
femoropopliteal lesions. Here, we employed intravascular ultrasound (IVUS) to investigate …

Drug-coated balloon treatment for femoropopliteal artery disease: the IN. PACT Global Study long lesion imaging cohort

D Scheinert, A Micari, M Brodmann… - Circulation …, 2018 - Am Heart Assoc
Background The IN. PACT Global Study was an international prospective single-arm clinical
trial to evaluate the safety and effectiveness of a drug-coated balloon in the treatment of …

[HTML][HTML] Nationwide trends in drug-coated balloon and drug-eluting stent utilization in the femoropopliteal arteries

A Mohapatra, Z Saadeddin, DJ Bertges… - Journal of vascular …, 2020 - Elsevier
Objective Drug-coated balloons (DCB) and drug-eluting stents (DES) have significantly
altered treatment paradigms for femoropopliteal lesions. We aimed to describe changes in …

[HTML][HTML] Simple classification and clinical outcomes of angiographic dissection after balloon angioplasty for femoropopliteal disease

N Kobayashi, K Hirano, M Yamawaki, M Araki… - Journal of Vascular …, 2018 - Elsevier
Objective Angiographic dissection is considered to be associated with restenosis. However,
little is known about the impact of the severity of angiographic dissection on future …